OligoG is a dry powder drug that has been shown to decrease the thickness of mucus in the lungs and may help individuals with cystic fibrosis clear mucus easier. OligoG may also help improve the effectiveness of some antibiotics. It is administered using a dry powder inhaler and also developed as a liquid for use with a nebulizer.

Status

Phase 2 trials of OligoG in people with CF were completed in Europe. No futher development in CF is planned at this time.

Sponsor

This program was sponsored by AlgiPharma and partially funded by the Cystic Fibrosis Foundation.